Some observations

We’re beginning to wonder if Livongo going public will become a watershed event. The stock itself is down over 35% since its highly successful IPO but more importantly look at what other diabetes stocks have done since that day- Dexcom initially rallied hit a high of $175.19 on August 28th and has since been selling off closing at $146.26 on Friday. Insulet continues its impressive run and is up over 15% since the Livongo debut. Tandem is basically treading water down just over 2%. The big winner has been MannKind up over 24%.

What does this all . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.